Seminars in Oncology Nursing
Volume 22 , Pages 28-34 , February 2006

Common Side Effects of Anti-EGFR Therapy: Acneform Rash

  • Rebecca Sipples

      Affiliations

    • Corresponding Author InformationAddress correspondence to Rebecca Sipples, APRN, MSN, Yale Comprehensive Cancer Center, 333 Cedar St, PO Box 208032, New Haven, CT 06520-8032

References 

  1. Herbst RS , Shin DM . Monoclonal antibodies to target epidermal growth factor receptor-positive tumors (A new paradigm for cancer therapy) . Cancer . 2002;94:1593–1611
  2. Schlessinger J . Cell signaling by receptor tyrosine kinases . Cell . 2000;103:211–225
  3. Moyer JD , Barbacci EG , Iwata KK , et al.   Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase . Cancer Res . 1997;57:4838–4848
  4. Brabender J , Danenberg KD , Metzger R , et al.   Epidermal growth factor receptor and HER2-neu mRNA expression in non–small cell lung cancer is correlated with survival . Clin Cancer Res . 2001;7:1850–1855
  5. Yano S , Kondo K , Yamaguchi M , et al.   Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition . Anticancer Res . 2003;23:3639–3650
  6. Saltz L , Meropol N , Loehrer PJ , et al.   Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor . J Clin Oncol . 2004;22:1201–1208
  7. Cunningham D , Humblet Y , Siena S , et al.   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer . N Engl J Med . 2004;351:337–345
  8. Kris MG , Natale RB , Herbst RS , et al.   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer (A randomized trial) . JAMA . 2003;290:2149–2158
  9. Pérez-Soler R , Chachoua A , Hammond LA , et al.   Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer . J Clin Oncol . 2004;22:3238–3247
  10. Soulieres D , Senzer NN , Vokes EE , et al.   Multicenter phase II study of erlotinib, an oral growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck . J Clin Oncol . 2004;22:77–85
  11. Albanell J , Rojo F , Averbach S , et al.   Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients (Histopathologic and molecular consequences of receptor inhibition) . J Clin Oncol . 2002;20:110–124
  12. Herbst RS , Giaccone G , Schiller JH , et al.   Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer (A phase III trial—INTACT 2) . J Clin Oncol . 2004;22:785–794
  13. Giaccone G , Herbst RS , Manegold C , et al.   Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer (A phase III trial—INTACT 1) . J Clin Oncol . 2004;22:777–784
  14. Herbst RS , LoRusso PM , Purdom M , et al.   Dermatologic side effects associated with gefitinib therapy (Clinical experience and management) . Clin Lung Cancer . 2003;4:366–369
  15. LoBuglio AF , Wheeler RH , Trang J , et al.   Mouse/human chimeric monoclonal antibody in man (kinetics and immune response) . Proc Natl Acad Sci U S A . 1989;86:4220–4224
  16. Shitara K , Kuwana Y , Nakamura K , et al.   A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced tumor activities . Cancer Immunol Immunother . 1993;36:373–380
  17. Harris M . Monoclonal antibodies as therapeutic agents for cancer . Lancet Oncol . 2004;5:292–302
  18. Baselga J . Why the epidermal growth factor receptor? The rationale for cancer therapy . Oncologist . 2002;7(suppl 4):2–8
  19. Baselga J , Pfister D , Cooper MR , et al.   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin . J Clin Oncol . 2000;18:904–914
  20. Needle MN . Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody . Semin Oncol . 2002;29(suppl 14):55–60
  21. Busam KJ , Capodieci P , Motzer R , et al.   Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 . Br J Dermatol . 2001;144:1169–1176
  22. Hollywood E . Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225 . Semin Oncol Nurs . 2002;18(suppl 2):30–35
  23. Jacot W , Bessis D , Jorda E , et al.   Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours . Br J Dermatol . 2004;151:238–241
  24. National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, v3.0 (CTCAE). Available at: http://ctep.cancer.gov (accessed March 3, 2005).
  25. Mohamed MK , Ramalingam S , Lin Y , et al.   Skin rash and good performance status (PS) predict improved survival with gefitinib for patients with advanced non–small cell lung cancer (NSCLC) [abstract 7097] . J Clin Oncol . 2004;22(suppl):14S
  26. Pérez-Soler R , Delord JP , Halpern A , et al.   HER1/EGFR inhibitor-associated rash (Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum) . Oncologist . 2005;10:345–356
  27. ERBITUX (cetuximab) [package insert]. New York, NY: ImClone Systems Incorporated, and Princeton, NJ: Bristol-Myers Squibb Company; August 2005.
  28. Iressa (gefitinib) tablets . Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2004; [package insert]. November
  29. Tarceva (erlotinib) tablets [package insert]. South San Francisco, CA: Genentech, Inc, and Melville NY: OSI Pharmaceuticals, Inc; 2004.

 Supported in part by a grant from Bristol-Myers Squibb Company.

PII: S0749-2081(06)00036-2

doi: 10.1016/j.soncn.2006.01.013

Seminars in Oncology Nursing
Volume 22 , Pages 28-34 , February 2006

Article Tools

* Image Usage & Resolution